Literature DB >> 738335

Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland.

J L Hayward, R D Rubens, P P Carbone, J C Heuson, S Kumaoka, A Segaloff.   

Abstract

Entities:  

Mesh：

Year:  1978        PMID： 738335     DOI： 10.1016/0014-2964(78)90238-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  16 in total

1.  Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer.

Authors:  Mónica Fernández-Sánchez; Armando Gamboa-Dominguez; Norma Uribe; Ana Cristina García-Ulloa; Diana Flores-Estrada; Myrna Candelaria; Oscar Arrieta
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Problems in evaluating response of primary breast cancer to systemic therapy.

Authors:  G Cocconi; B Di Blasio; G Alberti; G Bisagni; E Botti; G Peracchia
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

3.  Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer.

Authors:  G Bonadonna; P Valagussa; G Tancini; G Di Fronzo
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer.

Authors:  T Kojima; A Hoshino; K Ohara; O Kamiya; K Nagata; Y Ito; T Kinoshita; I Sugiura; M Yamada; H Sato
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 5.  Mistletoe therapy in oncology.

Authors:  M A Horneber; G Bueschel; R Huber; K Linde; M Rostock
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

6.  Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.

Authors:  D W Hedley; M Christie; R P Weatherby; I D Caterson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 7.  Functional magnetic resonance: biomarkers of response in breast cancer.

Authors:  Elizabeth A M O'Flynn; Nandita M DeSouza
Journal:  Breast Cancer Res       Date:  2011-02-23       Impact factor: 6.466

8.  The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study.

Authors:  S M Watkins
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

9.  Tamoxifen metabolism: pharmacokinetic and in vitro study.

Authors:  M C Etienne; G Milano; J L Fischel; M Frenay; E François; J L Formento; J Gioanni; M Namer
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

10.  Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.

Authors:  J Matsubara; T Nishina; Y Yamada; T Moriwaki; T Shimoda; T Kajiwara; T E Nakajima; K Kato; T Hamaguchi; Y Shimada; Y Okayama; T Oka; K Shirao
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.